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E-mail address: david.meek@cancer.org.uk (D.W. MThe E3 ubiqutin ligase, murne double-minute clone 2 (MDM2), promotes the degradation of p53
under normal homeostatic conditions. Several serine residues within the acidic domain of MDM2
are phosphorylated to maintain its activity but become hypo-phosphorylated following DNA dam-
age, leading to inactivation of MDM2 and induction of p53. However, the signalling pathways that
mediate these phosphorylation events are not fully understood. Here we show that the oncogenic
and cell cycle-regulatory protein kinase, polo-like kinase-1 (PLK1), phosphorylates MDM2 at one
of these residues, Ser260, and stimulates MDM2-mediated turnover of p53. These data are consistent
with the idea that deregulation of PLK1 during tumourigenesis may help suppress p53 function.
Structured summary:
MINT-7266353: MDM2 (uniprotkb:Q00987) physically interacts (MI:0915) with PLK1 (uniprotkb:P53350)
by pull down (MI:0096)
MINT-7266344, MINT-7266329: MDM2 (uniprotkb:Q00987) physically interacts (MI:0915) with PLK1
(uniprotkb:P53350) by anti bait coimmunoprecipitation (MI:0006)
MINT-7266250: PLK1 (uniprotkb:P53350) phosphorylates (MI:0217) p53 (uniprotkb:P04637) by protein
kinase assay (MI:0424)
MINT-7266241, MINT-7266318: PLK1 (uniprotkb:P53350) phosphorylates (MI:0217) MDM2 (uni-
protkb:P23804) by protein kinase assay (MI:0424)
MINT-7266231, MINT-7266805, MINT-7266264, MINT-7266299: PLK1 (uniprotkb:P53350) phosphory-
lates (MI:0217) MDM2 (uniprotkb:Q00987) by protein kinase assay (MI:0424)
 2009 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction checkpoint and is down-regulated in an ATM/ATR-dependent fash-The p53 tumour suppressor is a latent transcription factor that
plays a pivotal role in preventing tumour development [1,2]. p53 is
induced in response to a variety of cellular stresses, leading to cell
cycle arrest at the G1/S and G2/M boundaries or the onset of apop-
tosis. p53 is also regulated by a number of important partner pro-
teins including the E3 ubiquitin ligase, murne double-minute clone
2 (MDM2), which plays a critical role in the ubiquitylation and pro-
teasome-dependent degradation of p53 [3].
Polo-like kinase-1 (PLK1) is essential for the maturation of cen-
trosomes, entry into M phase, spindle formation and cytokinesis
[4]. PLK1 is a critical target of the DNA damage-induced G2/Mon behalf of the Federation of Euro
e 2; PLK1, polo-like kinase-1;
ORS, topoisomerase I binding,
eek).ion coincident with increases in p53 [5–7]. PLK1 is also thought to
be oncogenic. For example, constitutively active mutants of PLK1
can override the G2/M checkpoint [6] and transform NIH3T3 cells
[8]. Moreover, PLK1 is up-regulated in many human malignancies,
consistent with a role in tumourigenesis, and is widely considered
to be a potential therapeutic target [4].
In response to DNA damage, MDM2 undergoes rapid hypo-
phosphorylation of several important regulatory phospho-serine
residues within its acidic domain leading to loss of its ability to
promote p53 degradation [9]. Consistent with this model, phos-
phorylation of the acidic domain can stimulate its interaction with
a critical ubiquitylation signal in the core domain of p53 [10].
Although proteins kinases CK1, GSK3b and CK2 can modify several
sites within the acidic domain [11–13], we still do not have a com-
plete picture of the modifying enzymes that target this region. In
the present study we show that PLK1 can interact with and phos-
phorylate MDM2 at Ser260, one of these important serine residues.
We also show that PLK1 can stimulate the turnover of p53, andpean Biochemical Societies.
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depenent manner.2. Materials and methods
2.1. Cell lines, transfections and plasmids
HeLa (human cervical carcinoma-derived) cells and H1299
(human lung carcinoma-derived) cells were used in this study.
Transfections were carried out using Oligofectamine reagent
(Invitrogen Ltd.) as instructed by the manufacturer. Plasmids
expressing p53 [14] or wild-type MDM2 [15] have been described
previously.
2.2. Generation of tagged expression plasmids
The MYC-tagged human PLK1 construct was generated by PCR
ampliﬁcation of the MGC clone 2822226 (encoding human PLK1)
using the following primers:
PLK1 Forward primer: ATGAGTGCTGCAGTGACTGCA
PLK1 Reverse primer: TTAGGAGGCCTTGAGACG
The PCR product was cloned downstream of a Myc 9E10 tag in the
vector pSG5 (Stratagene). The inactive mutant PLK1 expression
plasmid was constructed by introducing a K82M substitution into
the wild-type PLK1 by site-directed mutagenesis as instructed by
the manufacturer (Stratagene Inc.). For expression in Escherichia
coli, the PCR product encoding PLK1 was cloned in the vector
pGEX4T (GE Healthcare). Subsequent expression and puriﬁcation
of the glutathione S-transferase (GST)-PLK1 fusion protein was car-
ried out as described elsewhere [16].
2.3. Antibodies and Western blot analysis
SDS–PAGE and western blotting was carried out using standard
conditions. Nitrocellulose membranes were probed for the pres-
ence of PLK1 (antibodies PL2 and PL6, Zymed Laboratories Inc.)
or for the MYC 9E10 tag, p53 (antibody DO1, Moravian Biotechnol-
ogy Ltd.; or CM-1, from Sir D. Lane, Dundee), MDM2 (SMP14, D12,
Santacruz Biotechnology Inc.; or 4B2, Moravian Biotechnology),
EGFP (ab6556, Abcam Ltd.), or actin (20–33, Sigma–Aldrich).
Appropriate secondary antibodies (HRP-conjugated) were from
DAKO. Proteins were detected by enhanced chemiluminescence
(Pierce Biotechnology Inc.).
2.4. Cell lysis and immunoprecipitation
These procedures were carried out as described elsewhere [17].
2.5. Luciferase reporter assays
H1299 cells were transfected with 50 ng/well of PG13 luciferase
reporter plasmid (containing the synthetic PG13 p53-responsive
element; [18]), 0.5 ng/well of SV-Renilla luciferase, 1 ng/well of
p53 expression vector, 10 ng/well of MDM2 expression vector
and 200 ng/well of PLK expression vector (all described above). Cell
extracts were prepared and the luciferase activities were deter-
mined as described previously [18].
2.6. Protein kinase assays
Puriﬁed untagged MDM2 proteins were a gift from Dr. Mark
Saville (University of Dundee). MDM2 kinase assays were per-
formed in 60 mM HEPES–NaOH, pH 7.5, 3 mMMgCl2, 3 mMMnCl2,1.2 mM DTT and 100 lM [c-32P]ATP (Amersham Pharmacia Bio-
tech, at a speciﬁc activity of 12 Ci/mmol) in a volume of 20 ll. As-
says were initiated by the addition of PLK1 protein kinase
(generally 13 units [pmol/min] of activity) and incubated at 30 C
for 30 min. Reactions were terminated by adding SDS sample buf-
fer and heating at 100 C for 2 min. Phosphorylated proteins were
detected following SDS–PAGE and autoradiography. Alternatively,
a non-radioactive assay was used in which the ATP concentration
was 100 lM and the phosphorylated proteins were detected by
Western blotting using a phospho-serine 260 speciﬁc antibody
(described below).
2.7. Generation and puriﬁcation of Ser260 phospho-speciﬁc antibody
A rabbit polyclonal phospho-speciﬁc antibody was raised
against the phosphopeptide: DSEDYS(phos)LSEEG (phospho-serine
260), coupled to keyhole limpet haemocyanin (Moravian Biotech-
nology Ltd.). Antibodies were afﬁnity-puriﬁed on sepharose 4B re-
sin to which the phosphorylated peptide had been covalently
coupled and passed through a second column containing the
unphosphorylated peptide to remove any antibodies that did not
recognise the phosphorylated epitope.
2.8. GST-pulldown experiments
The GST-MDM2 fusion proteins used in this study have been
described previously [19,20]. GST-pulldowns experiments were
performed as described elsewhere [17].3. Results
Analysis of the human MDM2 sequence revealed a PLK1 con-
sensus phosphorylation site (E/D-X-S-W-X-E: [21]) at Ser260 with-
in the acidic domain of the protein (Fig. 1A). To investigate whether
MDM2 is a substrate for PLK1, puriﬁed murine Mdm2 was incu-
bated in the presence of [c-32P]ATP and in the presence or absence
of puriﬁed recombinant PLK1. The data indicate that PLK1 can
phosphorylate Mdm2 in vitro (Fig. 1B). Recombinant PLK1 was also
able to phosphorylate human MDM2 (Fig. 1C); interestingly, p53,
previously reported to be a substrate for PLK1 [5], performed only
weakly as a PLK1 target in comparison with MDM2 (Fig. 1C). A pre-
viously characterised series of GST-(human) MDM2 fusion proteins
comprising overlapping regions of MDM2 were also tested as sub-
strates (these ‘‘mini-proteins” are termed MP1–MP4; see Fig. 1D;
[20]). The data revealed that there are at least two sites of phos-
phorylation, located within amino acids 203–282 (major site)
and 279–491 (minor site) (Fig. 1E). Following substitution of
Ser260 (equivalent to ser258 in murine Mdm2) with an alanine
residue in the MP3 GST-MDM2 fusion protein, phosphorylation
by PLK1 in vitro was abolished, conﬁrming that this residue is
the PLK1 target (Fig. 2A). A Ser260(P) phospho-speciﬁc antibody
was generated and puriﬁed: this antibody detected both human
MDM2 and murine Mdm2 only after they had been incubated in
the presence of ATP and active PLK1 in vitro (Fig. 2B). Notably
detection of phosphorylated murine Mdm2 was considerably
weaker than the human protein, possibly because there is a single
amino acid difference between the human and murine proteins in
the residues ﬂanking the phosphorylation site (Fig. 1A). Several at-
tempts to identify the minor phosphorylation site(s) between ami-
no acids 279 and 491, using mass spectrometry followed by Edman
degradation, failed to provide any rigorous identiﬁcation, possibly
owing to difﬁculties encountered in recovering sufﬁcient phos-
phorylated material.
To determine whether PLK1 could phosphorylate MDM2 in a
cellular context, wild-type or S260A mutant human MDM2 were
Fig. 1. PLK1 phosphorylates MDM2 in vitro. (A) Schematic of human MDM2 (upper) and murine Mdm2 (middle) amino acid sequences respectively, compared with a PLK1
consensus sequence (lower: [21]). The asterisk marks the phospho-acceptor residue. (B) Phosphorylation of murine Mdm2 by recombinant PLK1 in vitro. (C) Recombinant full
length his-tagged human p53 or untagged full length human MDM2 were phosphorylated by recombinant PLK1 in vitro. (D) Schematic showing the regions of MDM2 present
in a series of GST-MDM2 fusion ‘‘mini-proteins” MP1, -2, -3 and -4 used as substrates for protein kinase assays in panel (E) [19,20]. (E) GST alone or GST-MDM2 fusion
proteins were phosphorylated in vitro by recombinant PLK1 in vitro. Full length untagged human MDM2 protein (lane 7) was also used as a substrate.
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active PLK1. MDM2 was immunoprecipitated from cell extracts
and examined by western blotting using the Ser260P phospho-spe-
ciﬁc antibody. This antibody recognised wild-type MDM2 but not
the S260A mutant (Fig. 2C). Strikingly, this signal was enhanced
when wild-type PLK1, but not inactive mutant (K82M), was co-ex-
pressed, suggesting that PLK1 can phosphorylate Ser260 in cul-
tured cells. Attempts to detect changes in endogenous MDM2using the Ser260P phospho-speciﬁc antibody were inconclusive
(data not shown). We suspect that, since this residue lies within
a cluster of phosphorylation sites, the phosphorylation of neigh-
bouring residues may diminish the interaction of the antibody
with MDM2 thereby affecting the level of detectability.
To determine further whether MDM2 and PLK1 associate in
cultured cells, endogenous proteins were examined by IP/western.
Notably, endogenous PLK1 was observed to be present in
Fig. 2. PLK1 interacts with MDM2 in cultured cells and phosphorylates Ser260. (A) In vitro phosphorylation of wild-type or a S260A mutant of the MP3 mini-protein by
recombinant PLK1. (B) Phosphorylation of human MDM2 (upper two panels) and murine Mdm2 (lower two panels) in vitro. The kinase assay conditions were as described
above except that the ATP concentration was 100 lM and radiolabelled ATP was omitted. The phosphorylated MDM2/Mdm2 was detected using the rabbit polyclonal
phospho-speciﬁc antibody raised against the phosphopeptide: DSEDYS(phos)LSEEG (human phospho-serine 260; see Section 2). (C) Transient transfection of H1299 cells with
plasmids expressing wild-type or a S260A mutant of MDM2 together with wild-type or mutant (K82M) PLK1. After 48 h, MDM2 was immunoprecipitated from extracts using
antibodies SMP14 and 4B2. S260 phosphorylation, MDM2 and PLK1 proteins were detected by western blotting. (D) Endogenous PLK1 (antibodies PL2 and PL6) or MDM2
(antibodies SMP14 and 4B2) proteins were immunoprecipitated from HeLa cells. The immunoprecipitates were analysed by western blotting. HC shows the position of the
heavy chains of the antibody. Antibody alone (no extract) was run in the ﬁrst lane to conﬁrm the positions of the heavy chains. (E) HeLa cell lysates were incubated with GST
or the GST-MDM2 mini-proteins (MP1–4 (Fig. 2B)) immobilised on glutathione-coupled sepharose 4B beads. The bound proteins were analysed by western blotting using
anti-PLK1 antibodies (PL2 and PL6).
3546 S.S. Dias et al. / FEBS Letters 583 (2009) 3543–3548immunoprecipitates of MDM2 from HeLa cells (Fig. 2D, upper pa-
nel). Similarly, MDM2 was observed in immunoprecipitates for
PLK1 (Fig. 2D, lower panel). GST-pulldown experiments, in which
the MP1–MP4 mini-proteins described above were used to precip-
itate PLK1 from mammalian cell extracts, indicated that PLK1 can
associate with the C-terminal portion of MDM2 (amino acids
279–491) (Fig. 2E). Polo-like kinases contain a ‘‘polo-box domain”
which functions, in part, by interacting with a docking site contain-
ing tandem ser/thr residues that is distinct from the site of
phosphorylation and provides additional speciﬁcity [22]. The
C-terminal region of MDM2 contains several such tandem ser/thr
residues that could act as contact points for the polo-box domain
of PLK1 [22]. However, further analysis of the site(s) of interaction
in vitro, using deletion derivatives of MP4, was inconclusive (data
not shown).
To determine whether PLK1 could affect MDM2 function,
p53-null H1299 cells were transfected with plasmids encoding
p53 and/or MDM2 in the presence or absence of plasmids express-
ing active PLK1 or an inactive mutant of PLK1 (K82M substitution).
Conditions were adjusted empirically such that expression of
MDM2 reduced the level of p53 by about 50% (Fig. 3A). Under these
conditions, co-expression of active PLK1 further decreased the
levels of p53 (lanes 9–12). In contrast, the inactive PLK1 mutant
appeared to rescue p53 from MDM2-mediated depletion (lanes
5–8). No effect on p53 levels was observed when PLK1 and p53
were expressed in the absence of MDM2 either in p53-null/
MDM2-null MEFs (Fig. 3B) or in H1299 cells (data not shown).
These data are consistent with the idea that PLK1 mediates its ef-
fect on p53 levels by regulating MDM2. To determine whether
PLK1 could affect p53 function, p53-mediated transcription was
examined (Fig. 3C). In the absence of p53, PLK1 had no detectable
effect on expression of luciferase from the p53-responsive PG13
reporter plasmid. In contrast, PLK1 reduced p53-mediatedstimulation of gene expression (Fig. 3C), consistent with previously
published data [5]. Notably, inhibition of p53-dependent transcrip-
tion by PLK1 was proportionately greater in the presence of MDM2
than in its absence (Fig. 3C). These data suggest that PLK1 may
regulate p53 coordinately on at least two levels, one of which is
MDM2-dependent.
4. Discussion
In the present study we show that: (i) PLK1 can phosphorylate
MDM2 on Ser260 (Ser258 in murine Mdm2) both in vitro and in
cultured cells (Figs. 1 and 2) and (ii) endogenous PLK1 and
MDM2 proteins can interact in cultured cells; additionally, PLK1
interacts in vitro with the C-terminal domain of MDM2 which con-
tains several tandem ser/thr resides that could act as contact points
for the polo-box domain of PLK1 [22]. These data are consistent
with the idea that PLK1 can interact with and phosphorylate
MDM2 physiologically. We also show that PLK1 can inﬂuence the
levels and activity of p53 in a manner that requires MDM2
(Fig. 3). Interestingly, recently published data indicate that PLK1
phosphorylates and activates TOPORS, one of several other p53-di-
rected E3 ubiquitin- (and SUMO-) ligases, leading to increased p53
turnover [23]. Our data therefore ﬁt with the idea that PLK1 can
regulate p53 levels through parallel ubiquitylation pathways.
The acidic domain of MDM2 (Fig. 4) plays a critical functional
role by providing a second point of contact between MDM2 and
p53 (within the core region of p53) that permits efﬁcient ubiquity-
lation and degradation of p53 [10,24,25]. The acidic domain is also
a key target for numerous regulatory events that control p53 turn-
over. These include negative regulation by the ARF tumour sup-
pressor [26] and by various ribosomal proteins ([27] and
references therein). It is also modiﬁed by multiple phosphorylation
events that normally maintain MDM2 activity [9]. Among these,
Fig. 3. PLK1 negatively regulates p53 protein levels and transcriptional activity. (A)
Transient transfection of H1299 cells with plasmids expressing p53 [14], wild-type
MDM2 [15] and increasing amounts of either wild-type or kinase-inactive (K82M)
PLK1. The cells were lysed after 48 h and the proteins analysed by western blotting.
(B) p53/MDM2 double knock-out (DKO) cells were transiently transfected with
plasmids expressing p53 and either wild-type or inactive PLK1. Cells were
harvested and analysed as described in panel (A). (C) p53 transcriptional activity
was measured using the p53-responsive reporter plasmid PG13 (Section 2).
Experiments were performed in triplicate and the data presented as the
mean ± standard deviation. The level of p53 transcription in the presence of
MDM2 is signiﬁcantly reduced following the addition of PLK1 (P = 0.05).
Fig. 4. Context of PLK1 phosphorylation site in MDM2. The schematic shows the
salient features of MDM2 including the N-terminal p53 binding domain, the nuclear
localisation (NLS) and export (NES) sequences, the acidic domain, the zinc ﬁnger
(Zn) and the RING ﬁnger (RING). Part of the acidic domain is expanded to show the
sequence containing the cluster of phosphorylation sites that stimulate MDM2
function. These undergo DNA damage-induce hypo-phosphorylation through a
mechanism that is thought to involve DNA-PK/AKT-mediated inhibition of GSK3b,
one of the key protein kinases that modify this region (discussed in the text). PLK1
phosphorylates Ser260 within this cluster of regulatory residues. This site can also
be modiﬁed (weakly) by CK2 and possibly CK1 in vitro.
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Mdm2 (equivalent to residues 260/262 of human MDM2) had lost,
in part, the ability to mediate p53 degradation [9,13]. These sites
become hypo-phosphorylated in response to DNA strand breaks
leading to the inhibition of MDM2-mediated p53 turnover and
subsequent accumulation of active p53 [9,28] (Fig. 4). Recently
published data has indicated that DNA damage-induced loss of
phosphorylation of at least some of these sites can occur through
a mechanism involving DNA-PK/AKT-mediated inactivation of
GKS3b, one of the key protein kinases that modify this region
[28] (Fig. 4). As with GSK3b, the rapid down-regulation of PLK1
in response to DNA damage [6,7] ﬁts with the idea that hypo-phos-
phorylation may occur (at least in part) through inactivation of the
protein kinases that modify this region (Fig. 4).
Several other protein kinases are now known to phosphorylate
regulatory serine residues in the acidic domain [11–13] suggestingthat this region may act as an integration point that monitors cel-
lular homeostasis. As such, it may be sensitive to the action of var-
ious signalling molecules at any one time, each of which may be a
contributor rather than a dominant effector. We suggest that PLK1
may play its part by contributing to maintenance of phosphoryla-
tion of this domain during normal cell cycle progression as cells are
approaching mitosis. Regrettably, we have not been able to conﬁrm
this experimentally because siRNA-mediated knock-down of PLK1
arrests the cells in mitosis where they fail to express MDM2 (pre-
sumably because p53 cannot maintain its expression from the
highly condensed chromatin) and undergo rapid p53-independent
apoptosis (our unpublished data). Additionally, given that PLK1 is
down-regulated as part of the G2/M checkpoint [5–7], we would
also suggest that DNA damage-mediated inhibition of PLK1 might
contribute to relieving suppression of the p53 pathway. This would
also provide an additional, albeit indirect, layer of ATM-mediated
regulation of the p53 pathway and would ﬁt with the paradigm
that ATM orchestrates events following DNA damage in a multifac-
eted and coordinated manner.
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